Inrig Jula 4

What Happened
Inrig Jula, Chief Medical Officer of Travere Therapeutics (TVTX), sold a total of 1,779 shares in two open-market transactions on February 4, 2026, for aggregate proceeds of about $57,295. The trades were sales (code S): 1,547 shares at an average price of $32.11 (≈ $49,674) and 232 shares at an average price of $32.85 (≈ $7,621). These were routine sales under a pre-established plan and were used in part to cover tax obligations arising from restricted stock unit vesting.

Key Details

• Transaction date: February 4, 2026; Form 4 filed February 5, 2026 (timely filing).
• Trades:
  • 1,547 shares sold at weighted average $32.11 (price range reported $31.65–$32.61). Total ≈ $49,674. (Footnote F2)
  • 232 shares sold at weighted average $32.85 (price range reported $32.80–$32.90). Total ≈ $7,621. (Footnote F3)
• Aggregate shares sold: 1,779; aggregate proceeds ≈ $57,295.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Notable footnotes:
  • F1: Sales were made pursuant to a written 10b5-1 trading plan adopted May 28, 2025, and include sales to cover tax withholding on vested RSUs.
  • F2/F3: Weighted average prices and reported price ranges; full per-price breakdown available upon request to the SEC, issuer, or security holders.
• Transaction code: S = Sale. This was not an option exercise or gift.

Context
Sales done under a 10b5-1 plan are prearranged and often reflect routine portfolio or tax-management activity rather than a real-time statement of the insider’s view on the company. For retail investors, purchases are generally considered more informative than routine insider sales; this filing documents a predictable tax-related sale rather than a new investment decision.